ESCRS 2023: Orbis International details new education partnership and celebrates 20 years of Cybersight


The nonprofit marked a major milestone by announcing a suite of webinars with Heidelberg Engineering

Orbis International had much to celebrate during the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Vienna, Austria. The charity marked 20 years of its pioneering Cybersight platform, which will be the basis for a new programme with Heidelberg Engineering. Along with global education opportunities, the team effort will also fund new research into retinoblastoma, an ocular cancer that heavily impacts children in low-income countries. Coleman Cawe spoke to Ophthalmology Times Europe about what to expect from the partnership in the year ahead.

Editor's note: The following transcript has been lightly edited for clarity.

Coleman Cawe: I'm Coleman Cawe, Director of Fundraising and Communications, Orbis UK. We're delighted to be announcing our partnership with Heidelberg Engineering. We're partnering together to help eliminate avoidable blindness, particularly in low- and middle-income countries, where over 90% of the cases occur. And in addition to the funding that Heidelberg Engineering are giving to Orbis, it's also about knowledge and education to help eyecare professionals in low and middle income countries to deliver eye care in their local communities and help save sights day after day.

Our partnership with Heidelberg Engineering is twofold. We are delivering a series of webinars which will focus on imaging and the importance of imaging in low- and middle-income countries in particular, to help diagnose and treat eye conditions. We're also working on a piece of research together on retinoblastoma, a rare retinal cancer that affects 9,000 children, again, predominantly in low- and middle-income countries. And hopefully with that research, we're looking to see how we can improve outcomes, because they are still very poor. It's about 40% survival rate after 3 years. So, we're looking at how we can improve the outcomes around the access to eye care for earlier diagnosis and treatments for children.

In 2024, we'll be delivering our series of webinars. We will have one webinar each quarter during the year, which we'll be promoting through Cybersight, Orbis's telemedicine platform, which celebrates its 20th anniversary currently. So we're very proud of that achievement. We'll also be publicising our research as well. So that will be published in early 2024. We look forward to sharing the findings from that research to help improve outcomes for retinoblastoma.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.